MX2020007443A - Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias. - Google Patents

Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias.

Info

Publication number
MX2020007443A
MX2020007443A MX2020007443A MX2020007443A MX2020007443A MX 2020007443 A MX2020007443 A MX 2020007443A MX 2020007443 A MX2020007443 A MX 2020007443A MX 2020007443 A MX2020007443 A MX 2020007443A MX 2020007443 A MX2020007443 A MX 2020007443A
Authority
MX
Mexico
Prior art keywords
sup
derivatives
pyrazolo
pyrimidin
tetrahydro
Prior art date
Application number
MX2020007443A
Other languages
English (en)
Inventor
Francis Hubler
Mark Murphy
Dorte Renneberg
Simon Stamm
Sylvie Froidevaux
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2020007443A publication Critical patent/MX2020007443A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

La presente invención se refiere a derivados de fórmula (I) (ver Fórmula I) en donde el anillo A, X, Y, Z, RA, R1, R2, R3 y R4 son como se describe en la descripción, y en particular, por ejemplo, derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados a su preparación, a sales farmacéuticamente aceptables de los mismos, y a su uso como agentes farmacéuticos, a composiciones farmacéuticas que contienen uno o más compuestos de fórmula (I), y especialmente a su uso como moduladores del receptor C5a para el tratamiento, por ejemplo, de vasculitis y enfermedades inflamatorias.
MX2020007443A 2018-01-10 2019-01-09 Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias. MX2020007443A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018050598 2018-01-10
PCT/EP2019/050372 WO2019137927A1 (en) 2018-01-10 2019-01-09 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases

Publications (1)

Publication Number Publication Date
MX2020007443A true MX2020007443A (es) 2020-09-14

Family

ID=65012016

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007443A MX2020007443A (es) 2018-01-10 2019-01-09 Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias.

Country Status (29)

Country Link
US (2) US11608341B2 (es)
EP (1) EP3737684B1 (es)
JP (1) JP7014914B2 (es)
KR (1) KR102574564B1 (es)
CN (1) CN111566109B (es)
AR (1) AR114564A1 (es)
AU (1) AU2019207666B2 (es)
BR (1) BR112020013788A2 (es)
CA (1) CA3086310C (es)
CL (1) CL2020001817A1 (es)
DK (1) DK3737684T3 (es)
EA (1) EA202091641A1 (es)
ES (1) ES2933820T3 (es)
HR (1) HRP20221449T1 (es)
HU (1) HUE060515T2 (es)
IL (1) IL275868B2 (es)
LT (1) LT3737684T (es)
MA (1) MA51558B1 (es)
MX (1) MX2020007443A (es)
PH (1) PH12020500583A1 (es)
PL (1) PL3737684T3 (es)
PT (1) PT3737684T (es)
RS (1) RS63806B1 (es)
SG (1) SG11202006490YA (es)
SI (1) SI3737684T1 (es)
TW (1) TWI774905B (es)
UA (1) UA124694C2 (es)
WO (1) WO2019137927A1 (es)
ZA (1) ZA202004910B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007443A (es) * 2018-01-10 2020-09-14 Idorsia Pharmaceuticals Ltd Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias.
EP3740477A1 (en) 2018-01-19 2020-11-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
EP3740476A1 (en) * 2018-01-19 2020-11-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
US20220265658A1 (en) * 2019-07-09 2022-08-25 Idorsia Pharmaceuticals Ltd. Pharmaceutical composition comprising a tetrahydropyrazolopyrimidinone compound
US11193891B2 (en) * 2019-12-20 2021-12-07 Robert Bosch Gmbh Receptors and spacers for a fluorescence-based lead ion chemosensor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003218374A1 (en) * 2002-03-28 2003-10-13 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
WO2004033455A2 (en) * 2002-10-08 2004-04-22 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
US7906528B2 (en) * 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
ES2632975T3 (es) * 2010-06-24 2017-09-18 Chemocentryx, Inc. Antagonistas de C5aR
US8846656B2 (en) * 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
TWI736135B (zh) * 2013-03-01 2021-08-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
CN105705489B (zh) 2013-09-04 2019-04-26 百时美施贵宝公司 用作免疫调节剂的化合物
AU2014316682B2 (en) 2013-09-06 2018-11-22 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
US9738646B2 (en) * 2014-09-16 2017-08-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US9682940B2 (en) * 2015-08-25 2017-06-20 Janssen Pharmaceutica Nv Indazole derivatives useful as CB-1 inverse agonists
MX2020007443A (es) * 2018-01-10 2020-09-14 Idorsia Pharmaceuticals Ltd Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias.
EP3740476A1 (en) 2018-01-19 2020-11-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
EP3740477A1 (en) 2018-01-19 2020-11-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
US20220265658A1 (en) 2019-07-09 2022-08-25 Idorsia Pharmaceuticals Ltd. Pharmaceutical composition comprising a tetrahydropyrazolopyrimidinone compound

Also Published As

Publication number Publication date
PH12020500583A1 (en) 2021-06-14
DK3737684T3 (da) 2022-12-12
PT3737684T (pt) 2022-12-20
ES2933820T3 (es) 2023-02-14
BR112020013788A2 (pt) 2020-12-01
CA3086310A1 (en) 2019-07-18
US20230192708A1 (en) 2023-06-22
US11608341B2 (en) 2023-03-21
EA202091641A1 (ru) 2020-11-17
MA51558B1 (fr) 2022-12-30
TWI774905B (zh) 2022-08-21
EP3737684A1 (en) 2020-11-18
AU2019207666A1 (en) 2020-08-27
JP7014914B2 (ja) 2022-02-01
CL2020001817A1 (es) 2020-12-04
MA51558A (fr) 2021-04-14
TW202244047A (zh) 2022-11-16
JP2021510373A (ja) 2021-04-22
LT3737684T (lt) 2022-12-27
PL3737684T3 (pl) 2023-02-27
CN111566109A (zh) 2020-08-21
RS63806B1 (sr) 2023-01-31
SG11202006490YA (en) 2020-08-28
ZA202004910B (en) 2024-02-28
SI3737684T1 (sl) 2023-01-31
US20200369672A1 (en) 2020-11-26
EP3737684B1 (en) 2022-11-16
IL275868A (en) 2020-08-31
KR102574564B1 (ko) 2023-09-04
UA124694C2 (uk) 2021-10-27
HRP20221449T1 (hr) 2023-01-20
HUE060515T2 (hu) 2023-03-28
AR114564A1 (es) 2020-09-23
TW201930307A (zh) 2019-08-01
WO2019137927A1 (en) 2019-07-18
AU2019207666B2 (en) 2023-12-21
CN111566109B (zh) 2023-07-11
IL275868B2 (en) 2023-06-01
KR20200106061A (ko) 2020-09-10
CA3086310C (en) 2023-09-19

Similar Documents

Publication Publication Date Title
MX2020007443A (es) Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias.
MX2021010674A (es) Compuestos triciclicos condensados utiles como agentes anticancerigenos.
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
MX2014004738A (es) Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio.
MX2021004000A (es) Derivados de piperidina.
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
PH12019502562A1 (en) N-substituted indole derivatives
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
PH12017501699A1 (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
PH12015502632A1 (en) Cxcr7 receptor modulators
JOP20210259A1 (ar) مستقبل استروجين يحلل خمير يستهدف التحلل البروتيني
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
MX2021012223A (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.
PH12020552236A1 (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
MX2020013291A (es) Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis.
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
MX2022004215A (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4.
CR20210173A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2021015727A (es) Derivados de piridin-3-ilo.
TN2018000175A1 (en) Indane derivatives as mglur7 modulators